The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer Rokaya El AnsariLutfi AlfarsiAndrew R. Green Preclinical study Open access 21 March 2020 Pages: 1 - 12
The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer Jan J. JobsenHenk StruikmansEster Siemerink Preclinical study 30 March 2020 Pages: 13 - 21
Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival Rita A. MukhtarGregor KringsHope Rugo Preclinical study 02 April 2020 Pages: 23 - 29
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer Li PanXiang ChenJiayuh Lin Preclinical study 02 April 2020 Pages: 31 - 41
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes M. J. HassettH. LiR. S. Punglia Clinical trial 17 March 2020 Pages: 43 - 51
Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner Giovanna PanzironiGiuliana MoffaFederica Pediconi Clinical trial 17 March 2020 Pages: 53 - 60
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial Alessandra GennariFlavia FocaOriana Nanni Clinical trial 21 March 2020 Pages: 61 - 68
Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients Antônio Luiz FrassonMartina LichtenfelsFernanda Barbosa Clinical trial 25 March 2020 Pages: 69 - 75
Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience Ingeborg J. H. VriensElena M. ter Welle-ButalidVivianne C. G. Tjan-Heijnen Clinical trial Open access 31 March 2020 Pages: 77 - 86
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer Yvonne BrandbergHemming Johanssonthe Swedish Breast Cancer Group, the Austrian Breast, Colorectal Cancer Study Group, the German Breast Cancer Group Clinical trial Open access 31 March 2020 Pages: 87 - 96
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer Hannelore DenysCorina L. Martinez-MenaMona M. Van Steenberghe Clinical trial Open access 02 April 2020 Pages: 97 - 105
Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET/CT study Elias Immanuel Ordell SundelinNidal al-SulimanNiels Jessen Clinical trial 02 April 2020 Pages: 107 - 113
Behavior of metastatic breast cancer according to subtype Margot Van MechelenAnke Van HerckHans Wildiers Epidemiology 19 March 2020 Pages: 115 - 125
Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma Wei LiuWei LiZhenzhen Wang Epidemiology 29 March 2020 Pages: 127 - 134
Obesity-associated methylation in breast tumors: a possible link to disparate outcomes? Whitney L. DoKaren ConneelyLauren E. McCullough Epidemiology 31 March 2020 Pages: 135 - 144
Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers Kristen S. PurringtonDavid GorskiManohar Ratnam Epidemiology 31 March 2020 Pages: 145 - 154
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes Inna Y. GongAndrew T. YanKelvin K. W. Chan Epidemiology 31 March 2020 Pages: 155 - 165
The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients Yuan-Yuan LeiSuzanne C. HoWinnie Yeo Epidemiology 01 April 2020 Pages: 167 - 180
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome Anh N. LeJoanna HartonKara N. Maxwell Epidemiology 03 April 2020 Pages: 181 - 188
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer Takehiro HiraiAsuka NemotoMasaaki Matsuura Epidemiology 03 April 2020 Pages: 189 - 198
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors Maria Alice FranzoiCaroline VandeputteEvandro de Azambuja Epidemiology 03 April 2020 Pages: 199 - 209
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience J. WatanabeM. SaitoS. Nakamoto Epidemiology 05 April 2020 Pages: 211 - 220
Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support Serena OliveriGiulia OngaroGabriella Pravettoni Brief Report 31 March 2020 Pages: 221 - 224
HER2 borderline is a negative prognostic factor for primary malignant breast cancer Atanu BhattacharjeeJacinth RajendraShilpee Dutt Brief Report 31 March 2020 Pages: 225 - 231
